Stryker Corporation (SYK) is showing strength due to high procedure volumes and a significant capital equipment demand backlog, as highlighted by recent analyst upgrades. Barclays raised its price target to $469 with an Overweight rating, while Needham reiterated a Buy rating and increased its price target to $454, both recognizing the company’s strong performance across its MedSurg, Neurotechnology, and Orthopaedic segments. The company’s innovative medical technology solutions are driving its positive outlook.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Stryker Corporation (SYK) Gains Strength From Procedure Volumes and Capital Equipment Backlog
Stryker Corporation (SYK) is showing strength due to high procedure volumes and a significant capital equipment demand backlog, as highlighted by recent analyst upgrades. Barclays raised its price target to $469 with an Overweight rating, while Needham reiterated a Buy rating and increased its price target to $454, both recognizing the company’s strong performance across its MedSurg, Neurotechnology, and Orthopaedic segments. The company’s innovative medical technology solutions are driving its positive outlook.